Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enlivex ( (ENLV) ) has provided an announcement.
On April 3, 2025, Enlivex Therapeutics announced the dosing of the first patient in a Phase I trial to evaluate Allocetra™ for treating temporomandibular joint (TMJ) osteoarthritis. This trial, conducted at Sheba Medical Center, aims to assess the safety and efficacy of Allocetra™ in patients who have not responded to conventional therapies, potentially offering a novel treatment for a condition with no long-term solutions. The study’s outcomes could significantly impact Enlivex’s market positioning and provide new hope for TMJ osteoarthritis sufferers.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage company specializing in macrophage reprogramming immunotherapy. The company is developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages into their homeostatic state to address life-threatening conditions.
YTD Price Performance: -18.55%
Average Trading Volume: 133,411
Technical Sentiment Signal: Strong Buy
Current Market Cap: $20.89M
Learn more about ENLV stock on TipRanks’ Stock Analysis page.